Tell us a little bit about your background and about yourself.
 
Give us a brief overview of what are the previous approaches that have been used in the past for multiple myeloma testing.
 
So can you take a moment and talk to me about the new approach and the new algorithm that your laboratory is working on implementing?

 

So how does this new approach really benefit both hospitals across the country that we serve and the patients that they're trying to treat?

 

What else is the lab working on when it comes to our multiple myeloma testing and our algorithms?
 
 

Mellors et al.: Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances. 2020;4(10): 2236-2244